Probiodrug
| Probiodrug | |
|---|---|
| legal form | Corporation |
| ISIN | DE0007921835 |
| founding | 1997 |
| Seat | Halle (Saale) , Germany |
| management |
|
| Website | www.Probiodrug.de |
The Probiodrug AG ( EUR Euronext Amsterdam : PBD), headquartered in Halle (Saale) is a biopharmaceutical company with a strategic focus aimed at the development of drugs to treat Alzheimer's .
The company has developed a new therapy concept that intervenes in the development process and the early stages of the disease. The development approaches are aimed at the pyroglutamate Abeta (pGlu-Abeta), a key component of the neuro- / synaptotoxic pathology of the disease. The enzyme glutaminyl cyclase (QC) plays a crucial role in this process .
Probiodrug's lead product candidate, PQ912, has successfully completed a Phase 2a study . The company's pipeline also includes PBD-C06, an anti-pGlu-Abeta-specific monoclonal antibody that is in preclinical development. Probiodrug owns patents protecting the inhibition of QC as a therapeutic principle (medical use) and its product candidates (composition of matters). From its own perspective, the company has a leading position in this research area.
The company was founded in 1997 by Konrad Glund and Hans-Ulrich Demuth under the name ProBioTec GmbH for the development of antidiabetics of the then new class of active substances of DPP4 inhibitors . The name was changed to Probiodrug AG in 2001. The scientific competence of Probiodrug is based on the many years of expertise of its co-founder Demuth in the elucidation of the structure and function of enzymes that are involved in the modification of proteins and peptides that play a central role in pathological processes.
In 2004, under his leadership, it was demonstrated that the enzyme glutaminyl cyclase (QC) catalyzes the formation of certain β-amyloid species with a pyroglutamyl residue . These substances, "pGlu-Abeta" for short, are assigned a role in the development of Alzheimer's disease . Since then, the company has focused on the development of Alzheimer's therapies with the aim of playing a leading role in this area. The development approaches are aimed at lowering pGlu-Abeta, in particular through enzyme inhibition of glutaminyl cyclase. Probiodrug owns patents protecting the use of QC as a therapeutic principle and its product candidates as well as specific monoclonal antibodies against pGlu-Abeta.
The entire diabetes research with all patent rights was sold in 2004.
In October 2014 , the company went public and was listed on the Amsterdam Euronext Stock Exchange .
supporting documents
- ↑ Probiodrug - Alzheimer's researchers want to go public . Frankfurter Allgemeine Zeitung , October 11, 2014.
literature
- H. Lison, MFK Happel, F. Schneider, K. Baldauf, S. Kerbstat, B. Seelbinder, J. Schneeberg, M. Zappe, J. Goldschmidt, E. Budinger, UH Schröder, FW Ohl, S. Schilling, H .-U. Demuth, H. Scheich, KG Reymann, R. Rönicke: Disrupted cross-laminar cortical processing in β amyloid pathology precedes cell death . In: Neurobiology of Disease . tape 63 , March 2014, ISSN 1095-953X , p. 62-73 , doi : 10.1016 / j.nbd.2013.11.014 , PMID 24291517 .
- Markus Morawski, Stephan Schilling, Moritz Kreuzberger, Alexander Waniek, Carsten Jäger, Birgit Koch, Holger Cynis, Astrid Kehlen, Thomas Arendt, Maike Hartlage-Rübsamen, Hans-Ulrich Demuth, Steffen Roßner: Glutaminyl cyclase in human cortex: correlation with (pGlu ) -amyloid-β load and cognitive decline in Alzheimer's disease . In: Journal of Alzheimer's disease: JAD . tape 39 , no. January 2 , 2014, ISSN 1875-8908 , p. 385-400 , doi : 10.3233 / JAD-131535 , PMID 24164736 .